Helus Pharma (STU:R7E) Operating Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:R7E Helus Pharma Inc STU:R7E
38 GF Score
Price €6.39
! 2 Warning Signs
View Full Analysis

What is Helus Pharma Operating Margin %?

Helus Pharma STU:R7E +2.73% 38 Operating Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:R7E with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 939 Biotechnology companies, Helus Pharma ranks worse than 106496.17% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Helus Pharma's Operating Income for the three months ended in Mar. 2026 was €-41.40 Mil. Helus Pharma's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Helus Pharma's Operating Margin % for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Helus Pharma's Operating Margin % or its related term are showing as below:


STU:R7E's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.33
* Ranked among companies with meaningful Operating Margin % only.

Helus Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Helus Pharma's Operating Income for the three months ended in Mar. 2026 was €-41.40 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €-122.56 Mil.


Helus Pharma  (STU:R7E) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Helus Pharma Operating Margin % Related Terms


Helus Pharma Operating Margin % Historical Data

* Premium members only.

The historical data trend for Helus Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma Operating Margin % Chart

Helus Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Helus Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:R7E vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Helus Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helus Pharma Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helus Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Helus Pharma's Operating Margin % falls into.


STU:R7E
38GF Score
Helus Pharma Inc STU:R7E
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Helus Pharma's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (A: Mar. 2026 ) / Revenue (A: Mar. 2026 )
=-123.338 / 0
= %

Helus Pharma's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-41.398 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Helus Pharma (STU:R7E) has a Operating Margin % of 0.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Helus Pharma and its competitors. According to the industry distribution chart, Helus Pharma ranks #999999 out of 939 companies in the Biotechnology industry.
Is Helus Pharma's Operating Margin % too high?
Helus Pharma's current Operating Margin % is 0.00%. Based on the distribution chart, Helus Pharma ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helus Pharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #999999 out of 939 companies for Operating Margin %. This places Helus Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Helus Pharma and its competitors. Helus Pharma's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (STU:R7E) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Helus Pharma's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Helus Pharma (STU:R7E), the current Operating Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges HELP:USAHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
38GF Score

Get the complete analysis for STU:R7E

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.39
Price